{
    "nctId": "NCT01425476",
    "briefTitle": "Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors",
    "officialTitle": "Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "PG synthesis and metabolism",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women 18 years of age or older\n* Increased risk for breast cancer (demonstrated by strong family history \\[one 1st degree or two 2nd degree relatives\\], history of DCIS, IBC, or precancerous changes in breasts). OR Gail Model risk of developing IBC in a 5-year period of \\>1.66%\n* Women with a history of breast cancer, must be free of disease and finished with treatment\n* ECOG Performance Status score 0-1\n* Premenopausal women must not be pregnant.\n\nExclusion Criteria:\n\n* History of bilateral mastectomy, or bilateral breast irradiation\n* Significant medical or psychiatric problems making the participant a poor candidate\n* Evidence of excess use of narcotics or drug dependency\n* Have been pregnant and lactating in the past 2 years\n* Significant history of peptic ulcer disease or upper gastrointestinal bleeding\n* History of severe congestive heart failure that requires hospitalization or intervention\n* History of asthma requiring medication for treatment\n* Allergy to sulfonamides or NSAID medications\n* History of myocardial infarction or stroke\n* Currently on Coumadin\n* Currently on Tamoxifen (nolvadex),Evista (raloxifene), Femara (letrozole), Arimidex (anastrozole), or Aromasin (exemestane)\n* Undergone prior subaeolar breast surgery",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}